The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

Glioblastoma multiforme (GBM) is the most common malignant brain cancer that invades
normal brain tissue and impedes surgical eradication, resulting in early local recurrence and …

Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …

Objectives: To describe the most common serious adverse effects and organ toxicities
associated with emerging therapies for cancer that may necessitate admission to the ICU …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

The clinical application of chimeric antigen receptor (CAR) T‐cell therapy has rapidly
changed the treatment options for terminally ill patients with defined blood‐borne cancer …

Highlights•CAR-T cells face a battery of suppressive barriers in the solid tumor
microenvironment.•Safety, efficacy and specificity can be engineered directly into CAR …

Introduction: Glioblastoma (GBM) is a highly aggressive brain tumor and is one of the most
lethal human cancers. Chimeric antigen receptor (CAR) T cell therapy has markedly …

Cell-based immunotherapies have been selected for the front-line cancer treatment
approaches. Among them, CAR-T cells have shown extraordinary effects in hematologic …

The immunosuppressive tumor microenvironment represents a key challenge for chimeric
antigen receptor (CAR) T cells in solid tumors and includes the production of the inhibitory …